AstraZeneca Total Revenue vs Selling General Administrative Analysis

0A4J Stock

67.09 0.93 1.41%

AstraZeneca PLC financial indicator trend analysis is way more than just evaluating AstraZeneca PLC ADR prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AstraZeneca PLC ADR is a good investment. Please check the relationship between AstraZeneca PLC Total Revenue and its Selling General Administrative accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Revenue vs Selling General Administrative

Total Revenue vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AstraZeneca PLC ADR Total Revenue account and Selling General Administrative. At this time, the significance of the direction appears to have almost identical trend.

The correlation between AstraZeneca PLC's Total Revenue and Selling General Administrative is 0.96. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of AstraZeneca PLC ADR, assuming nothing else is changed. The correlation between historical values of AstraZeneca PLC's Total Revenue and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of AstraZeneca PLC ADR are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Total Revenue i.e., AstraZeneca PLC's Total Revenue and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Revenue

Total revenue comprises all receipts AstraZeneca PLC ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Selling General Administrative

Most indicators from AstraZeneca PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Tax Provision is likely to gain to about 932.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.3 B in 2024.

	2019	2020	2023	2024 (projected)
Gross Profit	19.6B	21.3B	24.5B	21.1B
Total Revenue	24.4B	26.6B	30.6B	26.1B

Gross Profit Total Revenue

AstraZeneca PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Capital Surpluse	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Other Liab	Net Tangible Assets	Accounts Payable	Other Stockholder Equity
Total Assets		0.83	0.9	-0.08	-0.71	0.77	0.68	0.83	0.82	0.82	0.92	-0.78	0.73	0.61	0.2	0.98	0.81	0.79	-0.67	0.92	0.85	0.28	-0.73	-0.39	0.8	-0.7
Short Long Term Debt Total	0.83		0.92	-0.25	-0.91	0.79	0.91	1.0	0.82	0.94	0.76	-0.83	0.86	0.73	0.61	0.9	0.91	0.94	-0.93	0.87	0.94	0.3	-0.84	-0.04	0.48	-0.81
Total Current Liabilities	0.9	0.92		-0.03	-0.91	0.87	0.83	0.9	0.9	0.98	0.76	-0.84	0.89	0.72	0.38	0.92	0.93	0.92	-0.81	0.96	0.95	0.17	-0.83	-0.18	0.68	-0.86
Total Stockholder Equity	-0.08	-0.25	-0.03		0.19	0.19	-0.11	-0.28	0.14	-0.06	-0.42	0.05	-0.01	0.08	-0.46	-0.22	0.01	0.09	0.43	-0.1	-0.1	-0.06	0.42	0.3	0.37	0.44
Retained Earnings	-0.71	-0.91	-0.91	0.19		-0.79	-0.92	-0.89	-0.81	-0.95	-0.6	0.83	-0.94	-0.8	-0.5	-0.78	-0.92	-0.9	0.94	-0.86	-0.96	-0.27	0.81	0.0	-0.44	0.87
Cash	0.77	0.79	0.87	0.19	-0.79		0.69	0.75	1.0	0.81	0.54	-0.9	0.87	0.71	0.27	0.77	0.89	0.87	-0.69	0.82	0.84	0.35	-0.65	0.07	0.66	-0.62
Other Assets	0.68	0.91	0.83	-0.11	-0.92	0.69		0.89	0.71	0.9	0.55	-0.76	0.87	0.85	0.5	0.74	0.89	0.93	-0.91	0.76	0.94	0.39	-0.67	0.08	0.45	-0.7
Long Term Debt	0.83	1.0	0.9	-0.28	-0.89	0.75	0.89		0.79	0.92	0.77	-0.81	0.82	0.71	0.64	0.9	0.89	0.92	-0.92	0.86	0.92	0.26	-0.83	-0.08	0.47	-0.81
Cash And Short Term Investments	0.82	0.82	0.9	0.14	-0.81	1.0	0.71	0.79		0.84	0.61	-0.91	0.88	0.72	0.28	0.82	0.91	0.88	-0.71	0.85	0.86	0.35	-0.69	0.01	0.68	-0.65
Net Receivables	0.82	0.94	0.98	-0.06	-0.95	0.81	0.9	0.92	0.84		0.69	-0.81	0.88	0.8	0.5	0.86	0.95	0.94	-0.86	0.94	0.97	0.13	-0.79	-0.13	0.6	-0.86
Good Will	0.92	0.76	0.76	-0.42	-0.6	0.54	0.55	0.77	0.61	0.69		-0.61	0.56	0.42	0.27	0.94	0.64	0.59	-0.64	0.83	0.72	0.2	-0.74	-0.54	0.59	-0.72
Short Term Investments	-0.78	-0.83	-0.84	0.05	0.83	-0.9	-0.76	-0.81	-0.91	-0.81	-0.61		-0.82	-0.76	-0.36	-0.79	-0.91	-0.86	0.81	-0.8	-0.87	-0.44	0.72	0.07	-0.64	0.73
Capital Surpluse	0.73	0.86	0.89	-0.01	-0.94	0.87	0.87	0.82	0.88	0.88	0.56	-0.82		0.74	0.26	0.77	0.88	0.9	-0.87	0.8	0.93	0.49	-0.76	0.17	0.47	-0.72
Inventory	0.61	0.73	0.72	0.08	-0.8	0.71	0.85	0.71	0.72	0.8	0.42	-0.76	0.74		0.43	0.62	0.91	0.8	-0.7	0.76	0.86	0.24	-0.36	-0.12	0.65	-0.54
Other Current Assets	0.2	0.61	0.38	-0.46	-0.5	0.27	0.5	0.64	0.28	0.5	0.27	-0.36	0.26	0.43		0.34	0.48	0.45	-0.59	0.38	0.42	-0.25	-0.41	-0.03	-0.08	-0.52
Total Liab	0.98	0.9	0.92	-0.22	-0.78	0.77	0.74	0.9	0.82	0.86	0.94	-0.79	0.77	0.62	0.34		0.84	0.82	-0.78	0.93	0.89	0.29	-0.81	-0.34	0.69	-0.78
Total Current Assets	0.81	0.91	0.93	0.01	-0.92	0.89	0.89	0.89	0.91	0.95	0.64	-0.91	0.88	0.91	0.48	0.84		0.94	-0.83	0.92	0.97	0.25	-0.67	-0.12	0.69	-0.76
Short Term Debt	0.79	0.94	0.92	0.09	-0.9	0.87	0.93	0.92	0.88	0.94	0.59	-0.86	0.9	0.8	0.45	0.82	0.94		-0.84	0.83	0.95	0.34	-0.72	0.1	0.59	-0.69
Intangible Assets	-0.67	-0.93	-0.81	0.43	0.94	-0.69	-0.91	-0.92	-0.71	-0.86	-0.64	0.81	-0.87	-0.7	-0.59	-0.78	-0.83	-0.84		-0.75	-0.9	-0.42	0.85	-0.06	-0.27	0.84
Common Stock	0.92	0.87	0.96	-0.1	-0.86	0.82	0.76	0.86	0.85	0.94	0.83	-0.8	0.8	0.76	0.38	0.93	0.92	0.83	-0.75		0.92	0.08	-0.75	-0.39	0.75	-0.84
Property Plant Equipment	0.85	0.94	0.95	-0.1	-0.96	0.84	0.94	0.92	0.86	0.97	0.72	-0.87	0.93	0.86	0.42	0.89	0.97	0.95	-0.9	0.92		0.35	-0.76	-0.1	0.63	-0.8
Other Current Liab	0.28	0.3	0.17	-0.06	-0.27	0.35	0.39	0.26	0.35	0.13	0.2	-0.44	0.49	0.24	-0.25	0.29	0.25	0.34	-0.42	0.08	0.35		-0.25	0.41	0.1	-0.01
Other Liab	-0.73	-0.84	-0.83	0.42	0.81	-0.65	-0.67	-0.83	-0.69	-0.79	-0.74	0.72	-0.76	-0.36	-0.41	-0.81	-0.67	-0.72	0.85	-0.75	-0.76	-0.25		0.07	-0.26	0.91
Net Tangible Assets	-0.39	-0.04	-0.18	0.3	0.0	0.07	0.08	-0.08	0.01	-0.13	-0.54	0.07	0.17	-0.12	-0.03	-0.34	-0.12	0.1	-0.06	-0.39	-0.1	0.41	0.07		-0.5	0.31
Accounts Payable	0.8	0.48	0.68	0.37	-0.44	0.66	0.45	0.47	0.68	0.6	0.59	-0.64	0.47	0.65	-0.08	0.69	0.69	0.59	-0.27	0.75	0.63	0.1	-0.26	-0.5		-0.37
Other Stockholder Equity	-0.7	-0.81	-0.86	0.44	0.87	-0.62	-0.7	-0.81	-0.65	-0.86	-0.72	0.73	-0.72	-0.54	-0.52	-0.78	-0.76	-0.69	0.84	-0.84	-0.8	-0.01	0.91	0.31	-0.37

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	63.4B	60.7B	61.4B	66.7B	76.7B	69.2B
Short Long Term Debt Total	15.6B	17.4B	16.2B	18.0B	20.7B	18.0B
Total Current Liabilities	18.1B	20.3B	22.6B	26.3B	30.2B	21.3B
Total Stockholder Equity	15.0B	12.5B	13.1B	15.6B	14.1B	11.4B
Retained Earnings	5.0B	6.4B	3.6B	3.1B	2.8B	5.2B
Cash	2.5B	3.9B	4.6B	6.7B	7.6B	4.8B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	3.9B
Long Term Debt	15.6B	17.4B	15.7B	17.5B	20.1B	17.7B
Cash And Short Term Investments	4.6B	5.7B	6.2B	8.0B	9.2B	6.7B
Net Receivables	5.2B	5.7B	8.8B	9.9B	11.4B	6.5B
Good Will	11.8B	11.7B	11.7B	11.8B	13.6B	12.9B
Capital Surpluse	4.4B	4.4B	7.9B	8.0B	9.2B	6.4B
Inventory	3.2B	4.0B	9.0B	4.7B	5.4B	4.6B
Other Current Assets	106M	99M	556M	398M	457.7M	385.6M
Total Liab	48.4B	48.2B	48.3B	51.1B	58.8B	53.6B
Total Current Assets	15.6B	19.5B	26.2B	22.6B	26.0B	19.8B
Short Term Debt	152M	160M	146M	286M	328.9M	184.4M
Intangible Assets	26.2B	22.0B	20.8B	20.9B	18.9B	18.8B
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	9.2B
Other Current Liab	4.9B	5.8B	4.5B	3.8B	4.4B	5.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	7.6B	8.8B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(25.4B)	(26.7B)
Accounts Payable	1.8B	2.4B	2.8B	2.6B	2.9B	2.5B
Other Stockholder Equity	(143M)	881M	111M	(1.6B)	(1.5B)	(1.4B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for AstraZeneca Stock Analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Total Revenue vs Selling General Administrative Analysis

Total Revenue vs Selling General Administrative

Total Revenue vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Total Revenue

Selling General Administrative

AstraZeneca PLC fundamental ratios Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC fundamental ratios Accounts

Also Currently Popular

Additional Tools for AstraZeneca Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Current Liabilities
Property Plant Equipment	+ 0.97	Net Receivables
Property Plant Equipment	+ 0.97	Total Current Assets

Property Plant Equipment	- 0.96	Retained Earnings
Net Receivables	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings
Intangible Assets	- 0.93	Short Long Term Debt Total
Intangible Assets	- 0.92	Long Term Debt
Total Current Assets	- 0.92	Retained Earnings